Zelira Therapeutics (ZLDAF) Stock Price, News & Analysis
Company Description
Zelira Therapeutics (OTC Link: ZLDAF) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $3.9M.
ZLDAF has gained 7.5% over the past year. Shares last traded at $0.3000.
This page collects what Stock Titan holds for ZLDAF, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Zelira Therapeutics (ZLDAF) stock last closed at $0.3000. Over the past 12 months, the stock has gained 7.5%. At a market capitalization of $3.9M, ZLDAF is classified as a micro-cap stock with approximately 13.1M shares outstanding.
Latest News
Zelira Therapeutics has 3 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 0 with negative movement. View all ZLDAF news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Zelira Therapeutics (ZLDAF) currently stands at 1.1 thousand shares, a new position with no short interest reported in the previous period, representing 0.0% of the float. Since August 2025, short interest has increased by 124.5%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Zelira Therapeutics (ZLDAF) currently stands at 4.5 days, up 331.7% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 331.7% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 4.5 days.
ZLDAF Company Profile & Sector Positioning
Zelira Therapeutics (ZLDAF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing ZLDAF often look at related companies in the same sector, including Mosaic Immunoengineering Inc (CPMV), Nascent Biotech (NBIO), Aptose Bioscienc (APTOF), Avenue Therapeutics Inc (ATXI), and Restart Life (NMLSF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ZLDAF's relative position within its industry.